openPR Logo
Press release

Janus Kinase (JAK) Inhibitor Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Aclaris, Arcutis, Celon Pharma, Galapagos, Gilead, Incyte, Novartis, Pfizer, Reistone

10-13-2023 04:32 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Janus Kinase (JAK) Inhibitor Pipeline Analysis (2023) Covering

As per DelveInsight's assessment, about 40+ prominent pharma and biotech giants are working on 45+ drugs in the Janus Kinase (JAK) Inhibitor pipeline landscape globally.

"Janus Kinase (JAK) Inhibitor Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Janus Kinase (JAK) Inhibitor Therapeutics Market.

The report provides a detailed description of the pipeline drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Janus Kinase (JAK) Inhibitor Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Janus Kinase (JAK) Inhibitor drugs.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development in the Janus Kinase (JAK) Inhibitor segment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details in the Janus Kinase (JAK) Inhibitor market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More About the Major Clinical, Commercial, and Regulatory Developments in the Janus Kinase (JAK) Inhibitor Market:
https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Leading Companies in the Janus Kinase (JAK) Inhibitor Market Landscape Include:
• AbbVie
• Aclaris Therapeutics
• Arcutis Biotherapeutics
• Celon Pharma
• Dizal Pharmaceutical
• Galapagos
• Gilead Sciences
• Incyte Corporation
• Jiangsu Hengrui Medicine Co.
• Novartis
• Pfizer
• Reistone Biopharma
• Sierra Oncology
• Theravance Biopharma
And many more

Janus Kinase (JAK) Inhibitor Pipeline Products Covered in the Report Include
• ATI-2138: Aclaris Therapeutics
• CPL409116: Celon Pharma
• Filgotinib: Galapagos
• Golidocitinib: Dizal Pharmaceutical
• Itacitinib: Incyte Corporation
• Ivarmacitinib: Arcutis Biotherapeutics/Reistone Biopharma
• Momelotinib: Sierra Oncology
• Nezulcitinib : Theravance Biopharma
• RINVOQ: AbbVie
• Ritlecitinib: Pfizer
• Ruxolitinib: Incyte Corporation/Novartis
• TD 5202: Theravance Biopharma
And Many More

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Delveinsight's Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

JAK Inhibitors Assessment and Analysis Covered in the Report
• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Introduction
2. Executive Summary
3. Janus Kinase (JAK) Inhibitor: In-depth Overview
4. Pipeline Therapeutics & Comparative Analysis
5. Therapeutic Assessment
6. Janus Kinase (JAK) Inhibitor - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment (Collaborations, Licensing/Partnering, Acquisition -Deal Value Trends)
8. Late-Stage Products (Phase III)
9. Mid-Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Pre-clinical and Discovery Stage Products
12. Inactive Products
13. Janus Kinase (JAK) Inhibitor Key Companies
14. Janus Kinase (JAK) Inhibitor Key Products
15. Janus Kinase (JAK) Inhibitor Unmet Needs
16. Janus Kinase (JAK) Inhibitor - Market Drivers and Barriers
17. Janus Kinase (JAK) Inhibitor Future Perspectives and Conclusion
18. Janus Kinase (JAK) Inhibitor Analyst Views
19. Appendix
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Tenosynovitis Market
https://www.delveinsight.com/report-store/tenosynovitis-market

Checkpoint Inhibitor Refractory Cancer Market
https://www.delveinsight.com/report-store/checkpoint-inhibitor-refractory-cancer-market

Encephalomyelitis Market
https://www.delveinsight.com/report-store/encephalomyelitis-market

FENEBRUTINIB Market
https://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast

Non-Muscle Invasive Bladder Cancer Market
https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market

Nrg1 Fusion Cancer Pipeline Insight
https://www.delveinsight.com/report-store/nrg1-fusion-cancer-pipeline-insight

Acute Pyelonephritis Market
https://www.delveinsight.com/report-store/acute-pyelonephritis-market

Chronic Refractory Gout Market
https://www.delveinsight.com/report-store/chronic-refractory-gout-market

Complicated Urinary Tract Infections Market
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

Congestive Heart Failure (CHF) Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market

Glomerulonephritis Market
https://www.delveinsight.com/report-store/glomerulonephritis-market

Metastatic Uveal Melanoma (MUM) Market
https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market

Musculoskeletal Pain Market
https://www.delveinsight.com/report-store/musculoskeletal-pain-market

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/recurrent-head-and-neck-cancer-squamous-cell-carcinoma-market

Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

Limb Girdle Muscular Dystrophy (LGMD) Market
https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-market

Lower-Limb Spasticity Market
https://www.delveinsight.com/report-store/lower-limb-spasticity-market

Hemiplegia Market
https://www.delveinsight.com/report-store/hemiplegia-market

Global Kinase Inhibitor in Autoimmune Diseases Market
https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market

Hereditary Spastic Paraplegias Market
https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market

Amebiasis Market
https://www.delveinsight.com/report-store/amebiasis-market

Galactosemia Market
https://www.delveinsight.com/report-store/galactosemia-market

Generalized Pustular Psoriasis Market
https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market

Hepatic Impairment Market
https://www.delveinsight.com/report-store/hepatic-impairment-market

Tuberous Sclerosis Complex Market
https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market

Amyloidosis Market
https://www.delveinsight.com/report-store/amyloidosis-market

BRAF-Mutant Metastatic Melanoma Market
https://www.delveinsight.com/report-store/braf-mutant-metastatic-melanoma-market

Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market

Hepatitis D Market
https://www.delveinsight.com/report-store/hepatitis-d-market

Hyperkalemia Market
https://www.delveinsight.com/report-store/hyperkalemia-market

Vasomotor symptoms (Hot flashes/Night sweats) Market
https://www.delveinsight.com/report-store/vasomotor-symptoms-market

Balloon Valvuloplasty Device Market
https://www.delveinsight.com/report-store/balloon-valvuloplasty-market

Choroideremia Market
https://www.delveinsight.com/report-store/choroideremia-market

Chronic Hand Eczema Market
https://www.delveinsight.com/report-store/chronic-hand-eczema-market

Complex Regional Pain Syndrome Market
https://www.delveinsight.com/report-store/complex-regional-pain-syndrome-crps-market

Diffuse Large B-cell Lymphoma Market
https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market

Hypersomnia Market
https://www.delveinsight.com/report-store/hypersomnia-market

Lamellar Ichthyosis (LI) Market
https://www.delveinsight.com/report-store/lamellar-ichthyosis-market

Ulcerative Colitis (UC) Market
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market

Vernal Keratoconjunctivitis Market
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market-insight

Endocarditis Market
https://www.delveinsight.com/report-store/endocarditis-market

Essential Thrombocythemia (ET) Market
https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights

Hepatorenal Syndrome Market
https://www.delveinsight.com/report-store/hepatorenal-syndrome-market

Pancreatic Ductal Carcinoma Market
https://www.delveinsight.com/report-store/pancreatic-ductal-carcinoma-market

Tenosynovial Giant Cell Tumors (TSGCTs) Market
https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market

Trauma Fixation Devices Market
https://www.delveinsight.com/report-store/trauma-devices-market

Usher Syndrome Market
https://www.delveinsight.com/report-store/usher-syndrome-market

Vulvar Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/vulvar-squamous-cell-carcinoma-market

Wide Neck Bifurcation Intracranial Aneurysms Market
https://www.delveinsight.com/report-store/wide-neck-bifurcation-intracranial-aneurysms-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Janus Kinase (JAK) Inhibitor Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Aclaris, Arcutis, Celon Pharma, Galapagos, Gilead, Incyte, Novartis, Pfizer, Reistone here

News-ID: 3249511 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Inhibitor

Advances in KRAS Inhibitor Development
The development of KRAS inhibitors has been a significant advancement in the field of oncology, offering new hope for patients with cancers driven by KRAS mutations. KRAS, a key gene involved in cell signaling, is frequently mutated in various cancers, including lung, colorectal, and pancreatic cancers. These mutations lead to uncontrolled cell growth and division, making KRAS a critical target for cancer therapy. Download Report: https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size Historically, KRAS was considered an undruggable target
Breakthroughs in KRAS Inhibitor Research
KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable." Download
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030. Understanding Checkpoint Inhibitor Refractory Cancer Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of
Fibroblast Growth Factor Receptor Inhibitor Market - Maximizing Therapeutic Pote …
Newark, New Castle, USA: The "Fibroblast Growth Factor Receptor Inhibitor Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Fibroblast Growth Factor Receptor Inhibitor Market: https://www.growthplusreports.com/report/fibroblast-growth-factor-receptor-inhibitor-market/8933 This latest report
Global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) Market Forecast 2023- …
The global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) market research report helps target customers understand the important driving factors and future opportunities of the industry. The report includes the dynamics of the macro environment such as the latest situation of the war between Russia and Ukraine, the update of monetary policy, and the impact of inflation on the market. Apart from this, the report studies key market developments such as
Avionic and electronic component corrosion inhibitor
Super CORR A was originally developed for the U.S. Air Force to comply with Mil-DTL-87177B (formerly Mil-L-87177A) specifications. A water displacing lubricant and corrosion protection compound that prevents avionic as well as electrical and electronic components from systems failures caused by corrosion. It is now the industry standard for electrical corrosion protection, for in service maintenance by both military and commercial aircraft major repair and overhaul (MRO) facilities worldwide. Super CORR